Login
Navigate Fool.com
Will PTLA beat
the market?
Community Rating: 5 Stars: The Best

24.44 0.14 (0.58%)

Quote as of

Extended Hours: $24.44 $0.00 (0.00%)
Quote as of (NASDAQ)


company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $24.09
Previous Close $24.30
Daily Range $23.80 - $24.86
52-Week Range $19.59 - $31.48
Market Cap $1.0B
P/E Ratio 2.85
Dividend (Yield) $0.00 (0.0%)
Volume 221,825
Average Daily Volume 462,993
Current FY EPS -$3.51

How do you think PTLA
will perform against the market?

Top PTLA Bull/Bear Pitches

 

TTime0917 (< 20)
Submitted June 19, 2014

Is on the move. Can be a rocky climb.

0 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted January 9, 2014

My initial impression of Portola is that it is a valid biopharma with reasonable prospects that doesn not currently deserve a one billion dollar valuation. I'm unclear how developmental Factor Xa inhi … More

0 Replies Reply Report this Post

News & Commentary

Why Portola Pharmaceuticals Inc. Stock Swooned

Portola shares flounder despite the company announcing another collaboration with Daiichi Sankyo. Find out what could have upset investors.

Sector Update: Healthcare Shares Edge Lower

Wednesday’s Top Biotech Stories: Orexigen, Portola, and Regeneron

Orexigen, Portola, and Regeneron could all make waves across the health care sector this Wednesday morning.

Warfarin's Loss is Johnson & Johnson's Gain

Factor Xa-inhibiting anticoagulants like Johnson & Johnson's Xarelto are rapidly winning prescriptions away from warfarin and Boehringer's Pradaxa.

3 Stocks That Escaped Biotech's March Madness

Agios Pharmaceuticals (AGIO), Chimerix (CMRX), and Portola (PTLA) overcame widespread selling in biotech last month thanks to important, potentially game-changing therapies.

An Interview With Portola Pharmaceuticals CEO Bill Lis

Motley Fool analyst Max Macaluso discusses Portola Pharmaceuticals' pipeline and approach to research and development with CEO Bill Lis.

Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals

Horizon Pharma, Prothena, and Portola Pharmaceuticals could all make health care headlines this morning. Here’s why.

Here's Why Big Pharma is Rooting for Portola

Pfizer (PFE), Bristol-Myers (BMY), Johnson & Johnson (JNJ) and Bayer (BAYRY) stand to make big money if Portola's anti-coagulant antidote succeeds.

What You Need to Know About Portola Pharmaceuticals Inc's Anticoagulant Gamechangers

Learn how Portola Pharmaceuticals may soon become a leader in the thrombosis prophylaxis market.

See More PTLA News...

Sector

Industry

PORTOLA PHARMACEUTICALS INC COM USD0.001 (PTLA) Description

Portola Pharmaceuticals Inc is a biopharmaceutical company that develops & commercializes novel therapeutics in the areas of thrombosis other hematologic disorders & inflammation for patients who currently have limited or no approved treatment options. Website: http://www.portola.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks